Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients
Go back to Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 49.52 -0.48 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.00 | 52 Week High | $45.58 | |||
| Open | $49.04 | 52 Week Low | $37.82 | |||
| Day High | $49.57 | P/E | N/A | |||
| Day Low | $48.86 | EPS | $0.00 | |||
| Volume | 3,722,991 | |||||
| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 294.60 +5.78 (2.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $288.82 | 52 Week High | $139.79 | |||
| Open | $287.61 | 52 Week Low | $82.07 | |||
| Day High | $295.19 | P/E | 685.12 | |||
| Day Low | $287.20 | EPS | $0.43 | |||
| Volume | 197,209 | |||||
